Trial Profile
ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs ISIS 104838 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 22 Oct 2007 Status changed from in progress to completed.
- 28 Oct 2005 New trial record.